natgillin/translations-raw huggingface dataset:
It was also compared with placebo (a dummy treatment) when looking at patients with an acute illness (839 patients) and patients treated for an additional 24 days following hip fracture surgery (656 patients).In the treatment of VTE such as DVT and PE, Arixtra was compared with enoxaparin (DVT: 2,192 patients) or with unfractionated heparin (PE: 2,184 patients). 
Prav tako so ga primerjali s placebom (zdravljenjem brez zdravilne učinkovine), in sicer pri bolnikih z akutno boleznijo (839 bolnikov) in pri bolnikih, ki so bili zdravljeni nadaljnjih 24 dni po operaciji zloma kolka (656 bolnikov).Pri zdravljenju venskih tromboemboličnih dogodkov, kot sta globoka venska tromboza in pljučna embolija, so zdravilo Arixtra primerjali z enoksaparinom (globoka venska tromboza: 2 192 bolnikov) ali z nefrakcioniranim heparinom (pljučna embolija: 2 184 bolnikov).
In the treatment of superficial vein thrombosis, Arixtra was compared with placebo in one study of 3,000 patients with superficial vein thrombosis of the legs, without DVT. 
Pri zdravljenju površinske venske tromboze so zdravilo Arixtra primerjali s placebo v eni študiji s 3 000 bolniki s površinsko vensko trombozo nog brez globoke venske tromboze.
While there was one VTE or death for every 100 patients taking Arixtra, there were six for every hundred taking placebo. 
Venski tromboembolični dogodek ali smrt sta se pojavila pri enem bolniku od 100, ki so jemali zdravilo Arixtra, v primerjavi s šestimi bolniki od 100, ki so jemali placebo.
Arixtra was more effective than placebo in reducing the overall occurrence of VTE or death in patients with superficial vein thrombosis. 
Zdravilo Arixtra je bilo pri zmanjševanju celokupnega pojava venskih tromboemboličnih dogodkov ali smrti pri bolnikih s površinsko vensko trombozo učinkovitejše od placeba.
The full EPAR for Arixtra can be found here. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Arixtra je na voljo tukaj.
Arixtra (1.5 and 2.5 mg strengths) is also used to treat adults who have blood clots in the superficial veins of the legs (superficial venous thrombosis) but not in their deep veins (deep vein thrombosis, DVT). 
Zdravilo Arixtra (v 1,5 in 2,5 mg) je mogoče uporabljati tudi za zdravljenje odraslih, ki imajo krvne strdke in površinskih venah nog (površinska venska tromboza), a ne v globokih venah (globoka venska tromboza, DVT).
At higher strengths (5, 7.5 and 10 mg), Arixtra is used to treat DVT or pulmonary embolism (PE, clot in a blood vessel supplying the lungs). 
Zdravilo Arixtra v večjih jakostih (5 mg, 7,5 mg in 10 mg) se uporablja za zdravljenje globoke venske tromboze ali pljučne embolije (PE, tj. strdkov v krvnih žilah, ki oskrbujejo pljuča).
Arixtra has been studied for the prevention of and in the treatment of VTE. 
Zdravilo Arixtra so proučevali z vidika preprečevanja in zdravljenja venskih tromboemboličnih dogodkov.
In the prevention of VTEs, the recommended dose of Arixtra is 2.5 mg once a day by subcutaneous injection (under the skin). 
Za preprečevanje tromboemboličnih dogodkov je priporočeni odmerek zdravila Arixtra 2,5 mg enkrat na dan, ki se daje s subkutano injekcijo (pod kožo).
In the treatment of DVT or PE, the recommended dose is 7.5 mg once a day by subcutaneous injection, usually for seven days. 
Pri zdravljenju globoke venske tromboze ali pljučne embolije je priporočeni odmerek 7,5 mg enkrat na dan, ki se daje s subkutano injekcijo, navadno sedem dni.
Arixtra (1.5 and 2.5 mg strengths) is used to prevent venous thromboembolic events (VTEs, problems due to the formation of blood clots in the veins) in adults (aged 18 years or over) who are having major surgery to their legs, such as a hip or knee surgery. 
Zdravilo Arixtra (jakosti 1,5 mg in 2,5 mg) se uporablja za preprečevanje venskih tromboemboličnih dogodkov (VTE, tj. zapletov, ki jih povzročajo krvni strdki) pri bolnikih (starejših od 18 let) po velikih operativnih posegih na nogah, kot so operativno zdravljenje kolka ali kolena.
How does Arixtra work? 
Kako zdravilo Arixtra deluje?
What is Arixtra used for? 
Za kaj se zdravilo Arixtra uporablja?
For patients with unstable angina or myocardial infarction, the recommended dose is 2.5 mg once daily by subcutaneous injection, but the first dose is given intravenously (into a vein) through an existing line or as an infusion (drip) in patients with ST segment elevation. 
Za bolnike z nestabilno angino pektoris ali miokardnim infarktom je priporočeni odmerek 2,5 mg enkrat na dan s subkutano injekcijo, pri čemer se prvi odmerek daje intravensko (v veno) skozi obstoječo cevko ali kot infuzijo (kapalno infuzijo) pri bolnikih z dvigom spojnice ST. Zdravljenje se mora pričeti takoj po diagnozi in mora trajati do osem dni ali do odpusta bolnika iz bolnišnice.
In the treatment of superficial vein thrombosis, the recommended dose is 2.5 mg once a day by subcutaneous injection. 
Pri zdravljenju površinske venske tromboze znaša priporočeni odmerek zdravila Arixtra 2,5 mg enkrat, ki se daje s subkutano injekcijo.
How has Arixtra been studied? 
Kako je bilo zdravilo Arixtra raziskano?
What is Arixtra? 
Kaj je zdravilo Arixtra?
How is Arixtra used? 
Kako se zdravilo Arixtra uporablja?
The first compared the effects of Arixtra with those of enoxaparin in over 20,000 patients with unstable angina or myocardial infarction without ST segment elevation, and the second compared Arixtra with standard care (unfractionated heparin in eligible patients, or placebo) in over 12,000 patients with myocardial infarction with ST segment elevation. 
V drugi študiji pa so primerjali učinke zdravila Arixtra s standardnim zdravljenjem (nefrakcioniranim heparinom pri ustreznih bolnikih ali s placebom) pri več kot 12 000 bolnikih s miokardnim infarktom z dvigom spojnice ST.
Arixtra was at least as effective as the comparators in all of the studies that looked at the prevention of VTE and treatment of DVT and PE. 
Zdravilo Arixtra je bilo v vseh študijah, v katerih so proučevali preprečevanje venskih tromboemboličnih dogodkov in zdravljenje globoke venske tromboze in pljučne embolije, vsaj tako učinkovito kot primerjalna zdravila.
It is important to tell your doctor if you are taking: 
Pomembno je, da zdravniku poveste, če jemljete:
• if you are going to have an operation under anaesthesia. 
• če boste imeli operacijo v anesteziji.
• at least two to four times a year in patients with serum creatinine levels at the upper limit of normal and in elderly subjects 
• vsaj dva- do štirikrat letno pri bolnikih z ravnjo kreatinina v serumu na zgornji meji normalne vrednosti in pri starejših bolnikih.
Make sure to ask your doctor for advice regarding when you can start your treatment again; 
Zdravnika morate vprašati za nasvet, kdaj se lahko ponovno začnete zdraviti;
Signs of ‘lactic acidosis' are: 
Znaki “laktacidoze” so:
Erythema3 Urticaria3 
eritem3 urtikarija3
• if you have problems with your liver; 
• če imate težave z ledvicami;
• Renal failure or renal dysfunction (creatinine clearance <60 ml/min). 
• Ledvična odpoved ali ledvična disfunkcija (kreatininski očistek < 60 ml/min).
Consumption of alcohol and medicinal products containing alcohol should be avoided. 
Pitje alkohola in jemanje zdravil, ki vsebujejo alkohol, se odsvetujeta.
Follow your doctor's instructions about stopping and re-starting your medicine. 
Upoštevajte priporočila zdravnika o prekinitvi in ponovnem začetku jemanja zdravila.
This is a build-up of lactic acid in the blood that can cause death. 
To je kopičenje mlečne kisline v krvi, ki lahko povzroči smrt.
Further symptoms are reduced body temperature and heart beat. 
Dodatna simptoma sta znižana telesna temperatura in zmanjšan srčni utrip.
Due to the mechanism of action, decreased renal function will result in reduced efficacy of empagliflozin. 
Zaradi mehanizma delovanja bo zmanjšano delovanje ledvic povzročilo zmanjšano učinkovitost empagliflozina.
This helps to lower blood sugar levels, which are too high in patients with type 2 diabetes. 
To pripomore k zniževanju ravni krvnega sladkorja, ki so pri bolnikih s sladkorno boleznijo tipa 2 previsoke.
(≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), or very rare (<1/10,000), and not known (cannot be estimated from the available data). 
Pogostnosti so opredeljene kot zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥ 1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000) in zelo redki (<1/10.000) ali neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Synjardy should be discontinued, at least temporarily, until the situation is clarified. 
Jemanje zdravila Synjardy je treba vsaj začasno prekiniti, dokler se stanje ne razjasni.
Ketoacidosis is a condition in which substances called ‘ketone bodies' accumulate in the blood and which can lead to diabetic precoma. 
Ketoacidoza je stanje, v katerem se snovi, imenovane ‘ketonska telesa', nakopičijo v krvi, in lahko privede do diabetične predkome.
As this medicinal product contains metformin, the treatment must be discontinued 48 hours before elective surgery with general, spinal or peridural anaesthesia. 
Ker to zdravilo vsebuje metformin, je treba zdravljenje z njim prekiniti 48 ur pred elektivnim kirurškim posegom v splošni, spinalni ali epiduralni anesteziji.
Patients should be instructed to notify these signs immediately to their physicians if they occur, notably if patients had a good tolerance to Synjardy before. 
Bolnikom naročite, da ob pojavu navedenih znakov nemudoma obvestijo svojega zdravnika, zlasti, če so bolniki pred tem dobro prenašali zdravilo Synjardy.
By blocking this protein, the medicine causes blood sugar to be removed via the urine. 
Z zaviranjem te beljakovine zdravilo povzroča izločanje krvnega sladkorja z urinom.
Stop taking Synjardy and see a doctor as soon as possible if you notice any of the following serious or potentially serious side effects: 
Takoj prenehajte jemati zdravilo Synjardy in se posvetujte z zdravnikom, če opazite katerega od naslednjih resnih ali potencialno resnih neželenih učinkov:
Physicians should alert the patients on the risk and on the symptoms of lactic acidosis. 
Zdravniki morajo bolnike opozoriti o tveganju in simptomih laktacidoze.
Reintroduction of Synjardy should then be discussed taking into account the benefit/risk ratio in an individual basis as well as renal function. 
O ponovni uvedbi zdravila Synjardy se je treba pogovoriti ob upoštevanju razmerja med koristjo in tveganjem pri posamezniku ter delovanja ledvic.
If necessary, the dose of the anti-hyperglycaemic medicinal product should be adjusted during therapy with the other medicinal product and on its discontinuation. 
Po potrebi je treba med zdravljenjem z drugim zdravilom ali ob njegovi ukinitvi prilagoditi odmerek antihiperglikemičnega zdravila.
In these cases, it is also recommended to check renal function before initiating treatment with Synjardy. 
V tovrstnih primerih je priporočljivo tudi preveriti delovanje ledvic pred pričetkom zdravljenja z zdravilom Synjardy.
Your doctor may ask you to stop taking Synjardy until you recover to prevent loss of too much body fluid; 
Vaš zdravnik vam bo morda naročil, da zdravilo Synjardy prenehate jemati, dokler ne okrevate, da preprečite izgubo prevelike količine telesnih tekočin;
Please note the following particular risk of lactic acidosis. 
Bodite pozorni predvsem na naslednja tveganja za laktacidozo.
Possible signs of losing too much fluid from your body are listed in section 4 ‘Possible side effects'. 
Možni znaki pretirane izgube tekočine iz telesa so našteti v poglavju 4, “Možni neželeni učinki”;
This medicinal product must not be used in patients with moderate or severe renal impairment (creatinine clearance <60 ml/min) (see sections 4.3 and 4.4). 
To zdravilo se ne sme uporabljati pri bolnikih z zmerno ali hudo ledvično okvaro (kreatininski očistek < 60 ml/min) (glejte poglavji 4.3 in 4.4).
Patients (%) achieving 
Bolniki (%) z izhodiščno vrednostjo
Body Weight (kg) at week 52b 
Telesna masa (kg) v 52. tednu b
In the acute conditions listed, metformin should be temporarily discontinued. 
Ob navedenih akutnih stanjih je treba začasno prekiniti zdravljenje z metforminom.
You will need to tell your doctor and stop taking this medicine before, or at the time of the X-ray and for 2 or more days after depending on how your kidneys are working. 
O tem boste morali obvestiti zdravnika in prenehati jemati to zdravilo pred ali na dan rentgenskega slikanja ter še 2 ali več dni po preiskavi, odvisno od delovanja ledvic.
It is important to you to comply with your medication intake, dietary instructions and regular exercise program because this can reduce the risk of lactic acidosis. 
Pomembno je, da pravilno jemljete zdravilo in upoštevate navodila glede prehrane ter program redne telesne vadbe, saj lahko s tem zmanjšate tveganje za nastanek laktacidoze.
N SBP (mmHg)3 
N Vrednost SBP (mmHg)2
• a medicine used to remove water from the body (diuretic), as Synjardy may increase the risk of losing too much fluid. 
• zdravilo, ki iz telesa odvaja tekočino (diuretik), saj lahko zdravilo Synjardy poveča tveganje za pretirano izgubo tekočine.
The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment with such medicinal products. 
Bolnika je treba s tem seznaniti in zlasti na začetku zdravljenja s temi zdravili pogosteje spremljati njegovo raven glukoze v krvi.
Lactic acidosis is a very rare, but serious (high mortality in the absence of prompt treatment), metabolic complication that can occur due to metformin accumulation. 
Laktacidoza je zelo redek, ampak resen presnovni zaplet (zaradi visoke umrljivosti, če ni takojšnjega zdravljenja), ki ga lahko povzroči kopičenje metformina.
It particularly affects patients whose kidneys are not working properly. 
Zlasti prizadene bolnike, ki imajo težave z delovanjem ledvic.
In case of lactic acidosis, the patient should be hospitalised immediately (see section 4.9). 
Ob pojavu laktacidoze je treba bolnika nemudoma sprejeti v bolnišnico (glejte poglavje 4.9).
Synjardy can also be combined with other medicines. 
Zdravilo Synjardy se lahko uporablja tudi v kombinaciji z drugimi zdravili.
Decreased renal function in elderly patients is frequent and asymptomatic. 
Zmanjšano delovanje ledvic je pri starejših ljudeh pogosto in asimptomatično.
a derived from postmarketing experience b see section 4.4 
a Izhaja iz izkušenj v obdobju trženja b
Therapy should usually not be resumed earlier than 48 hours following surgery and only after renal function has been reevaluated and found to be normal. 
Zdravljenje z zdravilom se navadno ne sme ponovno uvesti prej kot 48 ur po kirurškem posegu in šele po ponovni oceni delovanja ledvic, če je izvid normalen.
Empagliflozin is a reversible, highly potent (IC50 of 1.3 nmol) and selective competitive inhibitor of SGLT2. 
Empagliflozin je reverzibilen, izjemno močan (IC50 1,3 nmol) in selektiven kompetitiven zaviralec
You should stop taking Synjardy at least 48 hours before planned surgery with general, spinal or peridural anaesthesia and should not start again until at least 48 hours afterwards. 
Zdravilo Synjardy boste morali prenehati jemati vsaj 48 ur pred načrtovano operacijo v splošni, spinalni ali epiduralni anesteziji, zdravljenje pa smete znova nadaljevati najmanj 48 ur po posegu.
• if you need to have an injection of contrast agent that contains iodine, for example before an X-ray or scan. 
• če morate prejeti injekcijo jodiranega kontrastnega sredstva, npr. pred rentgenskim ali drugačnim slikanjem.
Synjardy should not be used in patients with type 1 diabetes. 
Zdravila Synjardy ne smejo uporabljati bolniki s sladkorno boleznijo tipa 1.
Diagnostic laboratory findings are decreased blood pH, plasma lactate levels above 5 mmol/l, and an increased anion gap and lactate/pyruvate ratio. 
Diagnostični laboratorijski izvidi kažejo znižano pH-vrednost krvi, raven laktatov v plazmi nad 5 mmol/l ter povečano anionsko vrzel in razmerje laktati/piruvat.
Metformin The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes. 
V prospektivni randomizirani študiji (UKDPS) je bila dokazana dolgoročna korist intenzivnega urejanja glukoze v krvi pri sladkorni bolezni tipa 2.
Difference from placebo1 
Razlika glede na placebo1
Other medicines and Synjardy Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Metformin, one of the active substances in this medicine, can cause a very rare (may affect up to 1 in 10,000 people) but serious side effect called ‘lactic acidosis'. 
Metformin, ena od zdravilnih učinkovin tega zdravila, lahko povzroči zelo redek (pojavi se lahko pri največ 1 od 10.000 bolnikov), a resen neželeni učinek “laktacidozo”.
Treatment with empagliflozin once daily resulted in statistically significant improvement in HbA1c, and 24 hour mean systolic and diastolic blood pressure as determined by ambulatory blood pressure monitoring (Table 6). 
Zdravljenje z empagliflozinom enkrat na dan je povzročilo statistično značilno izboljšanje HbA1c in 24-urnega povprečnega sistoličnega in diastoličnega krvnega tlaka, kot je bilo ugotovljeno z ambulantnim spremljanjem krvnega tlaka (preglednica 6).
• Diabetic ketoacidosis, diabetic pre-coma. 
• Diabetična ketoacidoza, diabetična predkoma.
ketoacidosisa, b Lactic acidosis3 
ketoacidozaa, b laktacidoza pomanjkanje vitamina
Of these, a total of 530 patients received empagliflozin as add-on to metformin plus insulin, of which 266 patients were treated with empagliflozin 10 mg and 264 with empagliflozin 25 mg. 
Od teh je skupno 530 bolnikov prejemalo empagliflozin kot dodatno zdravljenje k metforminu in insulinu, od teh pa je bilo 266 bolnikov zdravljenih z empagliflozinom 10 mg in 264 z empagliflozinom 25 mg.
5 Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
5 Prebavni simptomi, kot so slabost, bruhanje, driska, trebušne bolečine in zmanjšan tek, se najpogosteje pojavljajo na začetku zdravljenja ter večinoma spontano minejo.
Following administration of an oral [14C]-empagliflozin solution to healthy volunteers, approximately 96% of the drug-related radioactivity was eliminated in faeces (41%) or urine (54%). 
[14C]-empagliflozina se je pri zdravih prostovoljcih približno 96 % radioaktivnosti, povezane z zdravilom, izločilo v blato (41 %) ali urin (54 %).
The majority of drug-related radioactivity recovered in faeces was unchanged parent drug and approximately half of drug-related radioactivity excreted in urine was unchanged parent drug. 
Večina radioaktivnosti v blatu, povezane z zdravilom je bila nespremenjena izhodna učinkovina in približno polovica radioaktivnosti v urinu,
The frequency of patients with hypoglycaemic events was similar for empagliflozin and placebo as add-on to metformin. 
Pogostnost bolnikov s hipoglikemičnimi dogodki je bila podobna za empagliflozin in placebo kot dodatno zdravljenje k metforminu.
Lactic acidosis is characterised by acidotic dyspnea, abdominal pain and hypothermia followed by coma. 
Za laktacidozo so značilni acidozna dispneja, trebušne bolečine in hipotermija, ki ji sledi koma.
Hypoglycaemia (when used with sulphonylurea or insulin)1 
Presnovne in prehranske motnje hipoglikemija (pri uporabi s sulfonilsečnino ali insulinom)1
Vaginal moniliasis, vulvovaginitis, balanitis and other genital infection1, 2 
Infekcijske in parazitske bolezni vaginalna kandidoza, vulvovaginitis, balanitis in druge okužbe spolovil1,
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with renal failure or acute worsening of renal function. 
Primeri laktacidoze, o katerih so poročali pri bolnikih, ki jemljejo metformin, so se pojavili zlasti pri sladkornih bolnikih z okvaro ledvic ali akutnim poslabšanjem delovanja ledvic.
These may be medicines taken by mouth or insulin given by injection. 
To so lahko zdravila, ki se jemljejo peroralno (se zaužijejo) ali pa je to insulin, ki se injicira.
Difference from glimepiride1 (97.5% CI) 
Razlika glede na glimepirid1 (97,5-odstotni
Gastrointestinal symptoms3, 5 
Bolezni prebavil prebavni simptomi3, 5
• if you have uncontrolled diabetes, with e.g. severe hyperglycaemia (high blood glucose), nausea, vomiting, dehydration, rapid weight loss or ketoacidosis. 
• če imate nekontrolirano sladkorno bolezen s hudo hiperglikemijo (povišan krvni sladkor), slabostjo, bruhanjem, dehidracijo, hitro izgubo telesne mase ali ketoacidozo.
Do not stop taking Synjardy without first consulting your doctor. 
Če ste prenehali jemati zdravilo Synjardy Ne prenehajte jemati zdravila Synjardy, ne da bi se prej posvetovali z zdravnikom.
Your doctor may ask you to stop taking Synjardy until you have recovered; 
Vaš zdravnik vam bo morda naročil, da zdravilo Synjardy prenehate jemati, dokler ne okrevate;
There is an increased risk of lactic acidosis following excessive alcohol consumption (particularly in the case of fasting, malnutrition, or liver disease). 
Nevarnost laktacidoze je povečana pri prekomernem uživanju alkohola (zlasti ob postu, podhranjenosti ali jetrni okvari).
Liver function tests abnormalities3 Hepatitis3 
žolčnika in žolčevodov nenormalni izvidi testov jetrnih funkcij3 hepatitis3
• if you drink alcohol to excess, either every day or only from time to time (see section “Synjardy with alcohol”). 
• če imate težave z jetri; • če vsak dan ali samo občasno pijete prevelike količine alkohola (glejte poglavje “Zdravilo
Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away (see section 4). 
Takoj prenehajte jemati to zdravilo in se obrnite na zdravnika ali takoj pojdite v bolnišnico (glejte poglavje 4).
Due to its mechanism of action, patients taking Synjardy will test positive for glucose in their urine. 
Zaradi mehanizma delovanja bodo rezultati testov glukoze v urinu pri bolnikih, ki jemljejo zdravilo Synjardy, pozitivni.
There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic impairment due to the metformin active substance (see section 4.4)). 
Nevarnost laktacidoze je povečana pri akutni zastrupitvi z alkoholom (zlasti ob postu, podhranjenosti ali jetrni okvari, zaradi zdravilne učinkovine metformina (glejte poglavje 4.4)).
1 See subsections below for additional information 
1 Za dodatne informacije glejte spodnja podpoglavja.
Complicated urinary tract infection (e.g. pyelonephritis or urosepsis) occurred at a similar frequency in patients treated with empagliflozin compared to placebo. 
Zapletene okužbe sečil (npr. pielonefritis ali urosepsa) so se pri bolnikih, zdravljenih z empagliflozinom, pojavile s podobno pogostnostjo kot pri placebu.
Biotransformation Metformin is excreted unchanged in the urine. 
Metformin se nespremenjen izloči z urinom.
Table 1 Adverse reactions reported in placebo-controlled studies System organ class 
Preglednica 1: Neželeni učinki, o katerih so poročali v s placebom nadzorovanih študijah
The European Medicines Agency has waived the obligation to submit the results of studies with Synjardy in all subsets of the paediatric population in type 2 diabetes (see section 4.2 for information on paediatric use). 
Synjardy za vse podskupine pediatrične populacije s sladkorno boleznijo tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Dysuria2 
disurija2